will be made on May 24, 2019. The mentioned right will be further approved by the AGM 2019. 2. Approved to propose to the AGM to consider and approve the financial statement of the company for the fiscal
Consolidated Financial Results 1. Operating Results Revenues In the first half of fiscal year 2021, the total consolidated revenues were 10,386 million baht, decreasing of 655 million baht or 6% y-y. In the
accounts of 10,772 million baht or 12% of total accounts receivable, decreasing from 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. For default receivables in
10,470 million baht or 11% of total accounts receivable, comparing to that of 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. The delinquent account receivables
reduction in personal loan receivable by 517 million baht or 1% from end of last fiscal year. The main assets were attributed to the portfolio of net account receivables which shared 99% of total assets
No: AH 04052024 May 14th, 2024 Subject: Management Discussion & Analysis (MD&A) for the Financial Statements of the 1st Quarter of Fiscal Year 2024 Ended as of March 31, 2024 To: The President The
guideline for the expiration of Small Power Producer (SPP) Cogeneration plants, by revising the expiration period to be during 2016-2018, in line with NEPC’s resolution on May 30th, 2016. The 25 Firm-SPP
ให้สำนักงาน ก.ล.ต. สารบัญ หน้า 1. ข้อมูลเกี่ยวกับสำนักงานสอบบัญชี 1 2. กิจการที่อยู่ในเครือเดียวกันกับสำนักงานสอบบัญชี (network firm) 3 3. การจัดการภายในสำนักงานสอบบัญชี 3 4. ผลการตรวจสอบระบบการควบคุม
IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited